APO Research
Talk to an analyst

APO RESEARCH · REPORT

CGRP Targeting Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global CGRP Targeting Drugs Market Outlook and Growth Opportunities 2026

27 December 2025192 pages

Choose your research edition.

Industry ResearchCGRP Targeting Drugs Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal CGRP Targeting Drugs Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal CGRP Targeting Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CGRP Targeting Drugs Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal CGRP Targeting Drugs Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global CGRP Targeting Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for CGRP Targeting Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for CGRP Targeting Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for CGRP Targeting Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the CGRP Targeting Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the CGRP Targeting Drugs market include Alder Therapeutics, AbbVie Inc., Amgen Inc., Daiichi Sankyo Co., Ltd., Pfizer Inc., Lilly Inc., Lundbeck, Novartis International AG and Teva, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global CGRP Targeting Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of CGRP Targeting Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents CGRP Targeting Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global CGRP Targeting Drugs market.

CGRP Targeting Drugs Segment by Company

Alder Therapeutics

AbbVie Inc.

Amgen Inc.

Daiichi Sankyo Co., Ltd.

Pfizer Inc.

Lilly Inc.

Lundbeck

Novartis International AG

Teva

CGRP Targeting Drugs Segment by Type

CGRP Receptor Antagonists

CGRP Monoclonal Antibodies

CGRP Targeting Drugs Segment by Application

Specialty Clinic

Hospital

Others

CGRP Targeting Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global CGRP Targeting Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the CGRP Targeting Drugs key companies, revenue, market share, and recent developments.

3. To split the CGRP Targeting Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions CGRP Targeting Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify CGRP Targeting Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze CGRP Targeting Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CGRP Targeting Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CGRP Targeting Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CGRP Targeting Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global CGRP Targeting Drugs industry.

Chapter 3: Detailed analysis of CGRP Targeting Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of CGRP Targeting Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of CGRP Targeting Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. CGRP Targeting Drugs Industry Trends Table 2. CGRP Targeting Drugs Industry Drivers Table 3. CGRP Targeting Drugs Industry Opportunities and Challenges Table 4. CGRP Targeting Drugs Industry Restraints Table 5. Global CGRP Targeting Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global CGRP Targeting Drugs Revenue Share by Company (2021-2026) Table 7. Global CGRP Targeting Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global CGRP Targeting Drugs Key Company Manufacturing Base & Headquarters Table 9. Global CGRP Targeting Drugs Company, Product Type & Application Table 10. Global CGRP Targeting Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global CGRP Targeting Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of CGRP Receptor Antagonists Table 15. Significant Companies of CGRP Monoclonal Antibodies Table 16. Global CGRP Targeting Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global CGRP Targeting Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global CGRP Targeting Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global CGRP Targeting Drugs Sales Value Share by Type (2021-2026) Table 20. Global CGRP Targeting Drugs Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Specialty Clinic Table 22. Significant Companies of Hospital Table 23. Significant Companies of Others Table 24. Global CGRP Targeting Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global CGRP Targeting Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global CGRP Targeting Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global CGRP Targeting Drugs Sales Value Share by Application (2021-2026) Table 28. Global CGRP Targeting Drugs Sales Value Share by Application (2027-2032) Table 29. Global CGRP Targeting Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global CGRP Targeting Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global CGRP Targeting Drugs Sales Value Share by Region (2021-2026) Table 32. Global CGRP Targeting Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global CGRP Targeting Drugs Sales Value Share by Region (2027-2032) Table 34. Global CGRP Targeting Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global CGRP Targeting Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global CGRP Targeting Drugs Sales Value Market Share by Country (2021-2026) Table 37. Global CGRP Targeting Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global CGRP Targeting Drugs Sales Value Market Share by Country (2027-2032) Table 39. Alder Therapeutics Company Information Table 40. Alder Therapeutics Business Overview Table 41. Alder Therapeutics CGRP Targeting Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Alder Therapeutics CGRP Targeting Drugs Product Portfolio Table 43. Alder Therapeutics Recent Development Table 44. AbbVie Inc. Company Information Table 45. AbbVie Inc. Business Overview Table 46. AbbVie Inc. CGRP Targeting Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. AbbVie Inc. CGRP Targeting Drugs Product Portfolio Table 48. AbbVie Inc. Recent Development Table 49. Amgen Inc. Company Information Table 50. Amgen Inc. Business Overview Table 51. Amgen Inc. CGRP Targeting Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Amgen Inc. CGRP Targeting Drugs Product Portfolio Table 53. Amgen Inc. Recent Development Table 54. Daiichi Sankyo Co., Ltd. Company Information Table 55. Daiichi Sankyo Co., Ltd. Business Overview Table 56. Daiichi Sankyo Co., Ltd. CGRP Targeting Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Daiichi Sankyo Co., Ltd. CGRP Targeting Drugs Product Portfolio Table 58. Daiichi Sankyo Co., Ltd. Recent Development Table 59. Pfizer Inc. Company Information Table 60. Pfizer Inc. Business Overview Table 61. Pfizer Inc. CGRP Targeting Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Pfizer Inc. CGRP Targeting Drugs Product Portfolio Table 63. Pfizer Inc. Recent Development Table 64. Lilly Inc. Company Information Table 65. Lilly Inc. Business Overview Table 66. Lilly Inc. CGRP Targeting Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Lilly Inc. CGRP Targeting Drugs Product Portfolio Table 68. Lilly Inc. Recent Development Table 69. Lundbeck Company Information Table 70. Lundbeck Business Overview Table 71. Lundbeck CGRP Targeting Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Lundbeck CGRP Targeting Drugs Product Portfolio Table 73. Lundbeck Recent Development Table 74. Novartis International AG Company Information Table 75. Novartis International AG Business Overview Table 76. Novartis International AG CGRP Targeting Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Novartis International AG CGRP Targeting Drugs Product Portfolio Table 78. Novartis International AG Recent Development Table 79. Teva Company Information Table 80. Teva Business Overview Table 81. Teva CGRP Targeting Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Teva CGRP Targeting Drugs Product Portfolio Table 83. Teva Recent Development Table 84. Research Programs/Design for This Report Table 85. Authors List of This Report Table 86. Secondary Sources Table 87. Primary Sources List of Figures Figure 1. CGRP Targeting Drugs Product Image Figure 2. Global CGRP Targeting Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global CGRP Targeting Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global CGRP Targeting Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. CGRP Receptor Antagonists Image Figure 8. CGRP Monoclonal Antibodies Image Figure 9. Global CGRP Targeting Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global CGRP Targeting Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global CGRP Targeting Drugs Sales Value Share by Type (2021-2032) Figure 12. Specialty Clinic Image Figure 13. Hospital Image Figure 14. Others Image Figure 15. Global CGRP Targeting Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global CGRP Targeting Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global CGRP Targeting Drugs Sales Value Share by Application (2021-2032) Figure 18. Global CGRP Targeting Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global CGRP Targeting Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America CGRP Targeting Drugs Sales Value (2021-2032) & (US$ Million) Figure 21. North America CGRP Targeting Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe CGRP Targeting Drugs Sales Value (2021-2032) & (US$ Million) Figure 23. Europe CGRP Targeting Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific CGRP Targeting Drugs Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific CGRP Targeting Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America CGRP Targeting Drugs Sales Value (2021-2032) & (US$ Million) Figure 27. South America CGRP Targeting Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa CGRP Targeting Drugs Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa CGRP Targeting Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA CGRP Targeting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada CGRP Targeting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico CGRP Targeting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany CGRP Targeting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France CGRP Targeting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. CGRP Targeting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy CGRP Targeting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain CGRP Targeting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia CGRP Targeting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands CGRP Targeting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries CGRP Targeting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China CGRP Targeting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan CGRP Targeting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea CGRP Targeting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India CGRP Targeting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia CGRP Targeting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia CGRP Targeting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil CGRP Targeting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina CGRP Targeting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile CGRP Targeting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia CGRP Targeting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru CGRP Targeting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia CGRP Targeting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel CGRP Targeting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE CGRP Targeting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey CGRP Targeting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran CGRP Targeting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt CGRP Targeting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • CGRP Receptor Antagonists
  • CGRP Monoclonal Antibodies
Applications
  • Specialty Clinic
  • Hospital
  • Others
Companies covered
  • Alder Therapeutics
  • AbbVie Inc.
  • Amgen Inc.
  • Daiichi Sankyo Co., Ltd.
  • Pfizer Inc.
  • Lilly Inc.
  • Lundbeck
  • Novartis International AG
  • Teva

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global CGRP Targeting Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global CGRP Targeting Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 CGRP Targeting Drugs Market Dynamics
  1. 2.1 CGRP Targeting Drugs Industry Trends
  2. 2.2 CGRP Targeting Drugs Industry Drivers
  3. 2.3 CGRP Targeting Drugs Industry Opportunities and Challenges
  4. 2.4 CGRP Targeting Drugs Industry Restraints
3 CGRP Targeting Drugs Market by Company
  1. 3.1 Global CGRP Targeting Drugs Company Revenue Ranking in 2025
  2. 3.2 Global CGRP Targeting Drugs Revenue by Company (2021-2026)
  3. 3.3 Global CGRP Targeting Drugs Company Ranking (2024-2026)
  4. 3.4 Global CGRP Targeting Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global CGRP Targeting Drugs Company Product Type and Application
  6. 3.6 Global CGRP Targeting Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global CGRP Targeting Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 CGRP Targeting Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 CGRP Targeting Drugs Market by Type
  1. 4.1 CGRP Targeting Drugs Type Introduction
  2. 4.1.1 CGRP Receptor Antagonists
  3. 4.1.2 CGRP Monoclonal Antibodies
  4. 4.2 Global CGRP Targeting Drugs Sales Value by Type
  5. 4.2.1 Global CGRP Targeting Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global CGRP Targeting Drugs Sales Value by Type (2021-2032)
  7. 4.2.3 Global CGRP Targeting Drugs Sales Value Share by Type (2021-2032)
5 CGRP Targeting Drugs Market by Application
  1. 5.1 CGRP Targeting Drugs Application Introduction
  2. 5.1.1 Specialty Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global CGRP Targeting Drugs Sales Value by Application
  6. 5.2.1 Global CGRP Targeting Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global CGRP Targeting Drugs Sales Value by Application (2021-2032)
  8. 5.2.3 Global CGRP Targeting Drugs Sales Value Share by Application (2021-2032)
6 CGRP Targeting Drugs Regional Value Analysis
  1. 6.1 Global CGRP Targeting Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global CGRP Targeting Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global CGRP Targeting Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global CGRP Targeting Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America CGRP Targeting Drugs Sales Value (2021-2032)
  7. 6.3.2 North America CGRP Targeting Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe CGRP Targeting Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe CGRP Targeting Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific CGRP Targeting Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific CGRP Targeting Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America CGRP Targeting Drugs Sales Value (2021-2032)
  16. 6.6.2 South America CGRP Targeting Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa CGRP Targeting Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa CGRP Targeting Drugs Sales Value Share by Country, 2025 VS 2032
7 CGRP Targeting Drugs Country-level Value Analysis
  1. 7.1 Global CGRP Targeting Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global CGRP Targeting Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global CGRP Targeting Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global CGRP Targeting Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA CGRP Targeting Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada CGRP Targeting Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico CGRP Targeting Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany CGRP Targeting Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France CGRP Targeting Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. CGRP Targeting Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy CGRP Targeting Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain CGRP Targeting Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia CGRP Targeting Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands CGRP Targeting Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries CGRP Targeting Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China CGRP Targeting Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan CGRP Targeting Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea CGRP Targeting Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India CGRP Targeting Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia CGRP Targeting Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia CGRP Targeting Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil CGRP Targeting Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina CGRP Targeting Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile CGRP Targeting Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia CGRP Targeting Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru CGRP Targeting Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia CGRP Targeting Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel CGRP Targeting Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE CGRP Targeting Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey CGRP Targeting Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran CGRP Targeting Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt CGRP Targeting Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt CGRP Targeting Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt CGRP Targeting Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Alder Therapeutics
  2. 8.1.1 Alder Therapeutics Company Information
  3. 8.1.2 Alder Therapeutics Business Overview
  4. 8.1.3 Alder Therapeutics CGRP Targeting Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Alder Therapeutics CGRP Targeting Drugs Product Portfolio
  6. 8.1.5 Alder Therapeutics Recent Developments
  7. 8.2 AbbVie Inc.
  8. 8.2.1 AbbVie Inc. Company Information
  9. 8.2.2 AbbVie Inc. Business Overview
  10. 8.2.3 AbbVie Inc. CGRP Targeting Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 AbbVie Inc. CGRP Targeting Drugs Product Portfolio
  12. 8.2.5 AbbVie Inc. Recent Developments
  13. 8.3 Amgen Inc.
  14. 8.3.1 Amgen Inc. Company Information
  15. 8.3.2 Amgen Inc. Business Overview
  16. 8.3.3 Amgen Inc. CGRP Targeting Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Amgen Inc. CGRP Targeting Drugs Product Portfolio
  18. 8.3.5 Amgen Inc. Recent Developments
  19. 8.4 Daiichi Sankyo Co., Ltd.
  20. 8.4.1 Daiichi Sankyo Co., Ltd. Company Information
  21. 8.4.2 Daiichi Sankyo Co., Ltd. Business Overview
  22. 8.4.3 Daiichi Sankyo Co., Ltd. CGRP Targeting Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Daiichi Sankyo Co., Ltd. CGRP Targeting Drugs Product Portfolio
  24. 8.4.5 Daiichi Sankyo Co., Ltd. Recent Developments
  25. 8.5 Pfizer Inc.
  26. 8.5.1 Pfizer Inc. Company Information
  27. 8.5.2 Pfizer Inc. Business Overview
  28. 8.5.3 Pfizer Inc. CGRP Targeting Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Inc. CGRP Targeting Drugs Product Portfolio
  30. 8.5.5 Pfizer Inc. Recent Developments
  31. 8.6 Lilly Inc.
  32. 8.6.1 Lilly Inc. Company Information
  33. 8.6.2 Lilly Inc. Business Overview
  34. 8.6.3 Lilly Inc. CGRP Targeting Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Lilly Inc. CGRP Targeting Drugs Product Portfolio
  36. 8.6.5 Lilly Inc. Recent Developments
  37. 8.7 Lundbeck
  38. 8.7.1 Lundbeck Company Information
  39. 8.7.2 Lundbeck Business Overview
  40. 8.7.3 Lundbeck CGRP Targeting Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Lundbeck CGRP Targeting Drugs Product Portfolio
  42. 8.7.5 Lundbeck Recent Developments
  43. 8.8 Novartis International AG
  44. 8.8.1 Novartis International AG Company Information
  45. 8.8.2 Novartis International AG Business Overview
  46. 8.8.3 Novartis International AG CGRP Targeting Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Novartis International AG CGRP Targeting Drugs Product Portfolio
  48. 8.8.5 Novartis International AG Recent Developments
  49. 8.9 Teva
  50. 8.9.1 Teva Company Information
  51. 8.9.2 Teva Business Overview
  52. 8.9.3 Teva CGRP Targeting Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Teva CGRP Targeting Drugs Product Portfolio
  54. 8.9.5 Teva Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst